{"prompt": "['Novartis', 'Confidential', 'Page 69', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306']['Novartis', 'Confidential', 'Page 70', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306']['Novartis', 'Confidential', 'Page 71', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '9.7 Interim analyses', 'No interim analysis is planned in this study.', '9.8 Sample size calculation', 'The sample size calculation takes into account the following consideration:', 'To achieve at least 90% power (with multiplicity adjustment) for primary endpoint, to', 'demonstrate the non-inferiority of either of QVM149 dose VS. the free triple', 'combination of salmeterol/fluticasone + tiotropium in patients with uncontrolled', 'asthma for AQLQ at the week 24. With the assumption of 0.25 for the NI margin,', 'zero as the point estimation of the treatment difference, one-sided alpha level of', '0.025, and 0.8 of the standard deviation based on studies QMF149E2203 and', 'Kerstjens (2012);', 'If 10% dropout rate is assumed, then the calculation shows that the sample size of 1251', 'patients (i.e 417/arm) will provide 99% power with multiplicity adjustment as given in Figure', '9-1.', 'The sample size and power calculations are performed in R 3.1.2 with package gMCP.', '10 Ethical considerations', '10.1 Regulatory and ethical compliance informed consent procedures', 'This clinical study was designed and shall be implemented, executed and reported in', 'accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with', 'applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and', 'Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in', 'the Declaration of Helsinki.']\n\n###\n\n", "completion": "END"}